Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A
- 15 September 2013
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 19 (10), 1318-1324
- https://doi.org/10.1038/nm.3270
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational AssessmentPLoS Computational Biology, 2013
- F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined CohortHaemophilia, 2012
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia, 2011
- The Genetic Structure and History of Africans and African AmericansScience, 2009
- Inhibitors of Factor VIII in Black Patients with HemophiliaNew England Journal of Medicine, 2009
- Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpanPLoS Computational Biology, 2008
- Worldwide Human Relationships Inferred from Genome-Wide Patterns of VariationScience, 2008
- In-gel digestion for mass spectrometric characterization of proteins and proteomesNature Protocols, 2006
- The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter that Dictates ImmunodominanceImmunity, 2005
- Liver Transplantation in a HemophiliacNew England Journal of Medicine, 1985